What is the current stock price of Poxel S.A. (PXXLF)?

As of the latest market data, Poxel S.A. (PXXLF) is trading at $0.26. The stock has seen a loss of 0.00% today.

Does Poxel S.A. (PXXLF) pay a dividend?

Based on current data, Poxel S.A. does not have a confirmed active dividend policy.

What is the market cap of Poxel S.A.?

The current market capitalization of Poxel S.A. (PXXLF) is approximately unavailable.

PXXLF

Poxel S.A.·Healthcare

0.26

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.2552W H: $0.70

PXXLF NEWS

businesswire.com

Mar 31

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the deve.

businesswire.com

Mar 25

Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces that it has signed, on March 25, 2026, the new Tranche D PDR subscription agreement with IPF Partners ("IPF"), for €3.75 million as part of th.

businesswire.com

Feb 16

Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, reports today its annual revenue for the fiscal year ended December 31, 2025, and provides an update on its financial position. Consolidated Revenue Poxel generated consolidat.

businesswire.com

Feb 3

Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the implementation of an equity line with IRIS, known as “SmartATM® “ for a maximum amount of €5 million over five years (terms set out in the Appendix without this.

businesswire.com

Jan 30

POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the discharge from judicial reorganisation proceedings and ratification of the recovery plan by the Commercial Court of Lyon. This decision closes the observation pe.

Company Profile

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-01-06

Beta

1.54

Websitewww.poxelpharma.com↗